Compare Citius Pharmaceuticals Inc (CTXR) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Royal Caribbean Cruises Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Royal Caribbean Cruises Ltd trades at $281.56 (market cap $75.26B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5525.7× Citius Pharmaceuticals Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| CTXR | RCL | |
|---|---|---|
Market Cap | $13.62M | $75.26B |
Volume | 132,438 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $348.03 |
52-Week Low | $0.48 | $230.30 |
Typical Hold Time | 16 Days | 85 Days |
Enterprise Value | $3.79M | $97.91B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Royal Caribbean (RCL) trades at $282.36, down 2.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with Q1 and Q2 2026 earnings beats, revenue growth to $17.93B in 2025, and improving profit margins. Recent developments include a $3B investment in Sandals Resorts, expanding into the all-inclusive resort market. Analyst consensus remains positive with a $346.67 price target and 51% buy ratings.
RCL presents a compelling growth story with strong earnings momentum and strategic expansion, though investors face risks from high leverage, fuel cost volatility, and execution challenges from the Sandals acquisition. The stock's current valuation appears reasonable given growth prospects, but requires monitoring of debt levels and integration success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
